CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

021246Orig1s045 and 021087Orig1s062

OTHER REVIEW(S)
Division of Antiviral Products

REGULATORY PROJECT MANAGER LABELING REVIEW

Applications: 21087/S-062
21246/S-045

Name of Drug: TAMIFLU (oseltamivir phosphate) 30, 45, and 75 mg capsules
TAMIFLU (oseltamivir phosphate) 6 mg/mL oral suspension

Applicant: Hoffmann-La Roche, Inc.

Labeling Reviewed

Submission Date: June 21, 2012
Receipt Date: June 21, 2012
Amendment Date (labeling): December 21, 2012

Note: Last approved labeling for Tamiflu was NDA 21087/S-059 and NDA 21246/S-042 dated

Background and Summary Description:
On June 21, 2012, Roche submitted supplemental NDAs to expand the patient population and
support the dosing recommendation of Tamiflu for the treatment of influenza in infants less than
one year of age who have been symptomatic for no more than 2 days.

Two clinical studies served as the foundation for the sNDA clinical and label review: CASG 114
(WP20749) entitled “A Pharmacokinetic/Pharmacodynamic and Safety Evaluation of
Oseltamivir (Tamiflu) for the Treatment of Children Less Than 24 Months of Age with
Confirmed Influenza Infection” and WP22849 entitled “An Open Label, Prospective,
Pharmacokinetic/Pharmacodynamic, and Safety Evaluation of Oseltamivir (Tamiflu) in the
Treatment of Infants 0 to < 12 months of Age with Confirmed Influenza Infection.”

Review

GENERAL

1. Throughout the full prescribing information, clarification was made regarding the use of
   “subjects” versus “patients”.

2. In Section 6.1, “≥” or “<” symbols were revised to read “greater or less than”
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ELIZABETH G THOMPSON
12/21/2012

Chief agreement on review on Dec 20. Notified could sign off on Dec 21 without secondary signature.
FOOD AND DRUG ADMINISTRATION  
Center for Drug Evaluation and Research 
Office of Prescription Drug Promotion 
Division of Professional Drug Promotion

****Pre-decisional Agency Information****

Memorandum

Date: December 19, 2012

To: Elizabeth Thompson, MS, Regulatory Project Manager 
Division of Antiviral Products (DAVP)

From: Jessica Fox, PharmD, Regulatory Review Officer 
Sheila Ryan, PharmD, Group Leader 
Division of Professional Drug Promotion (DPDP)

Subject: NDA 021087/S-062; NDA 021246/S-045 
TAMIFLU (oseltamivir phosphate) capsules, for oral use 
TAMIFLU (oseltamivir phosphate) for oral suspension

As requested in DAVP's consult dated _, DPDP has reviewed a proposed _, for TAMIFLU, sent via email by DAVP on December 13, 2012.

DPDP's comments are provided directly below in the proposed _.

Thank you for the opportunity to provide comments. If you have any questions, please contact Jessica Fox at 301-796-5329 or at Jessica.Fox@fda.hhs.gov.

6 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JESSICA M FOX
12/19/2012
Memorandum

Date: December 12, 2012
To: Elizabeth Thompson, MS, Regulatory Project Manager
Division of Antiviral Products (DAVP)

From: Kemi Asante, PharmD, Regulatory Review Officer
Division of Consumer Drug Promotion (DCDP)

Subject: NDA 021087/S-62; NDA 021246/S-45
TAMIFLU (oseltamivir phosphate) capsules, for oral use
TAMIFLU (oseltamivir phosphate) for oral suspension

As requested in DAVP’s consult dated July 12, 2012, DCDP has reviewed the
TAMIFLU substantially complete prescribing information (PI) sent via email by
DAVP on November 29, 2012 and DMPP’s version of the patient package insert
(PPI) sent via email on December 11, 2012.

DCDP’s comments on the prescribing information are provided directly below in
DMPP’s version of the PPI.

Thank you for your consult. If you have any questions on the PPI, please contact
Kemi Asante at 6-7425 or at Kemi.Asante@fda.hhs.gov.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

OLUWASEUN A ASANTE
12/12/2012
Date: December 10, 2012

To: Debra B. Birnkrant, MD
   Director
   Division of Antiviral Products (DAVP)

Through: LaShawn Griffiths, MSHS-PH, BSN, RN
   Associate Director for Patient Labeling
   Division of Medical Policy Programs (DMPP)

   Barbara Fuller, RN, MSN, CWOCN
   Team Leader, Patient Labeling
   Division of Medical Policy Programs (DMPP)

From: Latonia Ford, RN, BSN, MBA
   Patient Labeling Reviewer
   Division of Medical Policy Programs (DMPP)

Subject: DMPP Review of Patient Labeling: Patient Package Insert (PPI) and Instructions for Use (IFU)

Drug Name (established name): TAMIFLU (oseltamivir phosphate)

Dosage Form and Route, Application Type/Number/Supplement Number:
capsules, NDA 21087/S-062
for oral suspension, NDA 21246/S-045

Applicant: Hoffmann-La Roche, Inc.
1 INTRODUCTION

On June 21, 2012, Hoffmann-La Roche, Inc. submitted Supplemental New Drug Applications (sNDA) 21087/S-062 for TAMIFLU (oseltamivir phosphate) capsules and (sNDA) 21246/S-045 for TAMIFLU (oseltamivir phosphate) for oral suspension. The Supplements provide proposed changes to the Prescribing Information and Patient Package Insert for the treatment of influenza in infants with a postconceptual age of at least 8 weeks to 1 year of age who have been symptomatic for no more than 2 days.

TAMIFLU (oseltamivir phosphate) capsules were originally approved October 27, 1999 for the treatment of uncomplicated acute illness due to influenza infections in adults who have been symptomatic for no more than 2 days. TAMIFLU (oseltamivir phosphate) for oral suspension was originally approved on December 14, 2000 for the treatment of uncomplicated acute illness due to influenza in patients older than one year of age who have been symptomatic for no more than 2 days.

On July 12, 2012, the Division of Antiviral Products (DAVP) requested that the Division of Medical Policy Programs (DMPP) review the Applicant’s proposed Patient Package Insert (PPI) and Instructions for Use (IFU) for TAMIFLU (oseltamivir phosphate) capsules and TAMIFLU (oseltamivir phosphate) for oral suspension.

This review is written in response to a request by DAVP for DMPP to review the Applicant’s proposed Patient Package Insert (PPI) and Instructions for Use (IFU) for TAMIFLU (oseltamivir phosphate) capsules and TAMIFLU (oseltamivir phosphate) for oral suspension.

2 MATERIAL REVIEWED

- Draft TAMIFLU (oseltamivir phosphate) capsules and TAMIFLU (oseltamivir phosphate) for oral suspension PPI received on June 21, 2012, and received by DMPP on November 28, 2012.
- Draft TAMIFLU (oseltamivir phosphate) capsules and TAMIFLU (oseltamivir phosphate) for oral suspension IFU received on June 21, 2012, and received by DMPP on November 28, 2012.
- Draft TAMIFLU (oseltamivir phosphate) capsules and TAMIFLU (oseltamivir phosphate) for oral suspension Prescribing Information (PI) received June 21, 2012, revised by the Review Division throughout the review cycle, and received by DMPP on November 28, 2012

3 REVIEW METHODS

To enhance patient comprehension, materials should be written at a 6th to 8th grade reading level, and have a reading ease score of at least 60%. A reading ease score of 60% corresponds to an 8th grade reading level. In our review of the PPI and IFU the target reading level is at or below an 8th grade level.
Additionally, in 2008 the American Society of Consultant Pharmacists Foundation (ASCP) in collaboration with the American Foundation for the Blind (AFB) published *Guidelines for Prescription Labeling and Consumer Medication Information for People with Vision Loss*. The ASCP and AFB recommended using fonts such as Verdana, Arial or APHont to make medical information more accessible for patients with vision loss. We have reformatted the PPI and IFU document using the Verdana font, size 11.

In our review of the PPI and IFU we have:
- simplified wording and clarified concepts where possible
- ensured that the PPI and IFU are consistent with the Prescribing Information (PI)
- removed unnecessary or redundant information
- ensured that the PPI meets the criteria as specified in FDA’s Guidance for Useful Written Consumer Medication Information (published July 2006)

4 CONCLUSIONS
The PPI and IFU are acceptable with our recommended changes.

5 RECOMMENDATIONS
- Please send these comments to the Applicant and copy DMPP on the correspondence.
- Our review of the PPI and IFU appended to this memorandum. Consult DMPP regarding any additional revisions made to the PI to determine if corresponding revisions need to be made to the PPI and IFU.

Please let us know if you have any questions.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

LATONIA M FORD
12/10/2012

BARBARA A FULLER
12/10/2012

LASHAWN M GRIFFITHS
12/10/2012
****Pre-decisional Agency Information****

Memorandum

Date: December 7, 2012
To: Elizabeth Thompson, MS, Regulatory Project Manager
    Division of Antiviral Products (DAVP)
From: Jessica Fox, PharmD, Regulatory Review Officer
    Division of Professional Drug Promotion (DPDP)
Subject: NDA 021087/S-062; NDA 021246/S-045
    TAMIFLU (oseltamivir phosphate) capsules, for oral use
    TAMIFLU (oseltamivir phosphate) for oral suspension

As requested in DAVP's consult dated July 12, 2012, DPDP has reviewed the
TAMIFLU substantially complete prescribing information, sent via email by DAVP
on November 29, 2012.

DPDP’s comments on the prescribing information are provided directly below in
the proposed labeling.

Thank you for your consult. If you have any questions, please contact Jessica
Fox at 301-796-5329 or at Jessica.Fox@fda.hhs.gov.

22 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following
this page
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JESSICA M FOX
12/07/2012
DATE: November 27, 2012

TO: Debra Birnkrant, M.D.
    Director, Division of Antiviral Products (DAVP)
    Office of New Drugs

FROM: Xikui Chen, Ph.D.
    Pharmacologist, Bioequivalence Branch
    Division of Bioequivalence and GLP Compliance
    Office of Scientific Investigations
    and
    Michael F. Skelly, Ph.D.
    Pharmacologist, Bioequivalence Branch
    Division of Bioequivalence and GLP Compliance
    Office of Scientific Investigations

THROUGH: Sam H. Haidar, R.Ph., Ph.D.
    Chief, Bioequivalence Branch
    Division of Bioequivalence and GLP Compliance
    Office of Scientific Investigations
    and
    William H. Taylor, Ph.D.
    Director,
    Division of Bioequivalence and GLP Compliance
    Office of Scientific Investigations

SUBJECT: Review of EIRs Covering NDAs 21-246/S-45 and
    21-087/S-62, Oseltamivir Phosphate, Sponsored by
    Hoffmann-LaRoche, Inc.

At the request of DAVP, the Division of Bioequivalence and GLP
Compliance (DBGC) conducted inspections for the following
pharmacokinetic studies:

**Study Number:** WP22849

**Study Title:** "An open-label, prospective,
pharmacokinetic/pharmacodynamic and safety
evaluation of oseltamivir (Tamiflu®) in the
treatment of infants 0 to <12 months of age
with confirmed influenza infection"
The audits included thorough examinations of study records, facilities, and equipment, and interviews and discussions with the firms' management and staff.

**Clinical Sites:**
- Pablo J. Sanchez, M.D. (Centers 140 and 166 in Study WP20749)
  University of Texas Southwestern Medical Center at Dallas
  Children's Medical Center
  Parkland Health and Hospitals Systems
  Dallas, TX
- Barbara Rath, M.D. (Center 204725 in Study WP22849)
  Charité Universitätsmedizin Berlin, Klinik für Pädiatrie mit Schwerpunkt, Pneumologie und Immunologie
  Berlin, Germany
- David W. Kimberlin, M.D. (Center 001 in Study WP20749)
  The Children's Hospital of Alabama
  The University of Alabama Hospital
  Birmingham, AL 35249

Clinical portions of the study were audited at the offices of Dr. Sanchez (by ORA Investigators; Form FDA 483 was issued), the offices of Dr. Rath (by ORA Investigator; no Form FDA 483 was issued), and the offices of Dr. Kimberlin (by ORA Investigator; no Form FDA 483 was issued). Dr. Sanchez's response to the observations was received at OSI on [See separate document uploaded into DARRTS.] The observations, Dr. Sanchez's response, and OSI/DBGC's evaluations follow.

1) **Failure to assure that an IRB was responsible for the initial and continuing review and approval of a clinical study.** Specifically, Manual of Procedures...
Version 1.0 dated December 19, 2006 and Version 2.0 dated November 11, 2009 was not approved by the IRB. The Manual of Procedures was observed to be an extension of the protocol and includes steps to be completed in the conduct of the clinical investigation.

Dr. Sanchez responded that because the instructions in the Manual of Procedures did not involve or affect protection of subject safety, review by the IRB was not required. The OSI/DBGC reviewers accept Dr. Sanchez's response as adequate.

2) An investigation was not conducted in accordance with the investigational plan. Specifically,

   1 Protocol section 8.2.3 Specimen Preparation, Handling, and Shipping states, Specific instruction on specimen preparation, handling and shipping will be provided in the Manual of Procedures (MOP) for this study. MOP section 6.1.2 PK Sample Preparation, Labeling and Shipment state "Plasma must be separated by centrifugation (e.g. 1500g for 10 minutes at 4 degrees Celsius) within 60 minutes of sample collection ... Plasma samples would be immediately stored in an upright position at or below -70 degrees C until ready to ship. The temperature of the freezer must be maintained and monitored."

   a. For 13 out of 25 subjects, there was inadequate documentation regarding the time Pharmacokinetic (PK) samples were placed at -70°C and the freezer used to store PK samples. At least two freezers were used to store samples at -70°C or below throughout the study. According to the Laboratory Research Coordinator, from two separate freezers were used simultaneously to store samples. These freezers were only identified by probe numbers; however, you failed to document the freezer each probe was monitoring. For these subjects, you failed to document the freezer used to store each sample at any given time and you failed to document the time each sample went into and was removed from the freezer.

      Five PK blood samples were acquired on Day 3 of the study for each subject. There were a total of 48 protocol deviations submitted for temperature excursions above -70°C.
b. For six (6) out of 25 subjects there were no records demonstrating the conditions of processing for the PK samples, including the centrifugation spin time and temperature.

2 Not all concomitant medications were recorded for five (5) of 26 subjects. Protocol Section 6.4 Concomitant Medications states, "Concomitant medications will be recorded on the specified CRF at Study Visit Days 1, 3, 5±1, and 10±2."

a. For Subject #222, Ferrous Sulfate was prescribed on study Day 3, 2/3/2007, but the Concomitant Medications Case Report Form (CRF) for this visit does not list Ferrous Sulfate. Ferrous Sulfate, with a start date of 2/14/2007, was found in a Concomitant Medications CRF that was completed 3/2/2007.

b. For Subject #226, Palivizumab (Synagis®) was given 2/23/2007 (Day One), and was not included in the CRF for Concomitant Medications.

c. For Subject #402, Oxacillin was being given intravenously from 8/6/2009 until 8/8/2009. The subject's Day One was 8/7/2009 and Oxacillin was not included in the CRF for Concomitant Medications.

d. For Subject #642, Palivizumab (Synagis®) was given 10/2/2009 (Day One) of the study, and was not included in the CRF for Concomitant Medications.

e. For Subject #643, Palivizumab (Synagis®) was given 10/5/2009 (Day One) of the study, and was not included in the CRF for Concomitant Medications.

Dr. Sanchez responded to observation 2)1a. that the temperature recording probes uniquely identified individual freezers. In addition, he provided a statement from Roche Laboratories that the short temperature excursions were within the documented range under which oseltamivir is stable. The OSI/DBGC reviewers accept Dr. Sanchez's response as adequate.

Dr. Sanchez responded to observation 2)1b. that during the study, upon recognition of the importance of documenting centrifugation conditions, the staff began to record them. The OSI/DBGC reviewers recommend that the deviations in recording are unlikely to have affected the study outcomes for the six subjects significantly.
Dr. Sanchez responded to observation 2)2 that a delay in filling the prescription for ferrous sulfate resulted in the child's parents not beginning its administration until 2/14/2007, and not reporting it to Dr. Sanchez until the visit on 3/2/2007, when he entered it into the concomitant medications records. He notes that the palivizumab doses were given before the first oseltamivir dose, and that the protocol did not require them to be listed as concomitant medications. He acknowledges that oxacillin should have been listed as a concomitant medication. The OSI/DBGC reviewers accept Dr. Sanchez's responses as adequate to address questions of protocol compliance, and recommend that the clinical pharmacology reviewer evaluate the possible impact of ferrous sulfate, palivizumab, and oxacillin on pharmacokinetics of oseltamivir and its metabolite.

3) Failure to prepare or maintain adequate case histories with respect to observations and data pertinent to the investigation and informed consent. Specifically,
1. Subject #236 was given the commercial drug oseltamivir on 9/15/09 at 16:15, after consent and after randomization. This subject was consented on 9/15/09 at 15:39. Randomization for the subjects occurred on 9/15/09 at 16:11. The commercial drug oseltamivir was not observed on the concomitant medications source documentation. This dose was also not listed on the Study Medication Dosing Record for this subject.
2. For six (6) out of 26 subjects enrolled in the study, there was no record of the time the informed consent form was signed in order to verify that study procedures did not occur before consent.
3. For four (4) out of 26 subjects, you failed to write the date you signed source documents that pertain to study procedures, including Progress Records and Physical Examination Source worksheets.
4. Subject #232 has a history of a brain cyst under neurologic evaluation; however, this was not listed on the Medical and Surgical History source documentation. Subject #232 was consented on 05/18/09.

Dr. Sanchez responds that subject #236 was treated with oseltamivir by a primary physician at 04:15 on 9/15/09, before entering the study, and as such the oseltamivir was not required by the protocol to be listed on the Study Medication Dosing Record. However, he acknowledges that it should have been listed as a concomitant medication. The OSI/DBGC reviewers
accept Dr. Sanchez's response as adequate, and recommend that
the clinical pharmacology reviewer consider the pre-study dose
of oseltamivir when evaluating pharmacokinetic data for this
subject.

Dr. Sanchez responds that the actual times and dates of events
in the study are supported by external documents and records,
such as electronic medical records and separate date records on
the documents. Since the time of the study, institutional
procedures have been amended to require detailed time and date
records.

Dr. Sanchez responds that the feature seen in the ultrasound
image in the coronal profile for subject #232 was not confirmed
by ultrasound in the sagittal profile, nor in a computed
tomography scan. Therefore, he regarded the questionable cyst
as likely absent. The OSI/DBGC reviewers accept Dr. Sanchez's
response as adequate.

Analytical Sites:

Study WP22849

Analytical portions of the studies were audited at

by ORA Investigator and OSI/DBGC

and OSI/DBGC Scientist . Following the inspection
at , Form FDA 483 was not issued. Following the inspection
at , Form FDA 483 was issued. response to the
observation was received on . The observation, response, and OSI/DBGC's evaluations follow.

1) The calibration failures associated with Pipettor 79, used
during testing of run 13 of Sponsor Study Number WP20749,
and Pipettor 9, used during testing of run 40 of Sponsor
Study Number WP20749, were not evaluated to determine the
calibration failure's adverse effects to the accuracy,
sensitivity and precision of the analytical results
reported for these runs.
The OSI/DBGC reviewers note that the calibrators and QC samples handled during runs 13 and 40 passed all run acceptance and system suitability criteria. Therefore, the pipette calibration failures had no consequences on data quality in these runs.

**Conclusions:**

Following the above inspections, the DBGC reviewers recommend the following:

- The clinical pharmacology reviewer should evaluate the possible impact of ferrous sulfate, palivizumab, and oxacillin on pharmacokinetics of oseltamivir and its metabolite, for subjects #222, 226, 402, 642, and 643.
- The clinical pharmacology review should consider the pre-study dose of oseltamivir when evaluating pharmacokinetic data for subject #236.
- All other data from these studies are acceptable for review.

**Final Classifications:**

**NAI:** Barbara Rath, M.D. (Center 204725 in Study WP22840)
Charité Universitätsmedizin Berlin, Klinik für Pädiatrie mit Schwerpunkt, Pneumologie und Immunologie Berlin, Germany
FEI 3001919105

**VAI:** Pablo J. Sanchez, M.D. (Centers 140 and 166 in Study WP20749)
University of Texas Southwestern Medical Center at Dallas; Children's Medical Center; Parkland Health and Hospitals Systems; Dallas, TX
FEI 3006996981

**NAI:** David W. Kimberlin, M.D. (Center 001 in Study WP20749)
The Children’s Hospital of Alabama; The University of Alabama Hospital; Birmingham, AL

**VAI:** (now closed)

**FEI**

Reference ID: 3221745
CC:
CDER OSI PM TRACK
OSI/DBGLPC/Taylor/Haidar/Dejernett/XChen/Skelly/CF
DAVP/Birnkrant/Thompson
OCP/DCPIV/Zheng

Draft: MFS 11/23/12
Edits: XC 11/26/12; SHH 11/26/2012, WHT 12/27/2012
DSI: 6368; O:\BE\EIRCOVER\21246and21087.hof.ose.doc
FACTS: 1434272
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MICHAEL F SKELLY
11/27/2012
See separate file for the response to Form FDA 483 by Dr. Sanchez.

XIKUI CHEN
11/27/2012

SAM H HAIDAR
11/28/2012

WILLIAM H TAYLOR
11/28/2012
Date: November 15, 2012

Reviewer: Morgan Walker, Pharm.D., M.B.A.
Division of Medication Error Prevention and Analysis

Team Leader: Jamie Wilkins Parker, Pharm.D.
Division of Medication Error Prevention and Analysis

Associate Director: Scott Dallas, RPh.
Division of Medication Error Prevention and Analysis

Drug Name and Strength: Tamiflu (Oseltamivir Phosphate)
Capsules: 30 mg, 45 mg, 75 mg
Powder for Oral Suspension: 6 mg/mL

Application Type/Number: NDA 021087/S-062 and 021246/S-045

Applicant: Hoffmann-La Roche, Inc.

OSE RCM #: 2012-1565

*** This document contains proprietary and confidential information that should not be released to the public.***
1 INTRODUCTION

This review evaluates the proposed package insert labeling for Tamiflu (Oseltamivir Phosphate) Capsules (NDA 021087/S-062) and Oral Suspension (NDA 021246/S-045) for areas of vulnerability that could lead to medication errors.

1.1 BACKGROUND

This efficacy supplement, NDA 021087/S-062 and 021246/S-045, provides for the dosing recommendation for the treatment of influenza in infants with a post conceptual age of at least 6 weeks to 1 year of age who have been symptomatic for no more than 2 days. It should be noted that both Tamiflu products share the same package insert labeling.

1.2 REGULATORY HISTORY

Tamiflu (Oseltamivir Phosphate) is currently marketed in the United States. Tamiflu Capsules were approved by the FDA on October 27, 1999 under NDA 021087. Tamiflu Oral Suspension was approved on December 14, 2000 under the NDA 021246.

1.3 PRODUCT INFORMATION

The following product information is provided in the June 21, 2012 submission.

- Active Ingredient: Oseltamivir Phosphate
- Indication of Use: For the treatment of influenza in patients 1 year and older who have been symptomatic for no more than 2 days, and for the prophylaxis of influenza in patients 1 year and older
- Route of Administration: Oral
- Dosage Form: Capsules and Oral Suspension
- Strength: Capsules: 30 mg, 45 mg, and 75 mg; Oral suspension: 6 mg/mL
- Dose and Frequency:
  - **Treatment of influenza**
    - Adults and adolescents (13 years and older): 75 mg twice daily for 5 days
    - Pediatric patients (1 year to 12 years of age): Based on weight twice daily for 5 days
    - Renally impaired patients (creatinine clearance 10-30 mL/min): Reduce to 75 mg once daily for 5 days
  - **Prophylaxis of influenza**
    - Adults and adolescents (13 years and older): 75 mg once daily for at least 10 days
      - Community outbreak: 75 mg once daily for up to 6 weeks
    - Pediatric patients (1 year and older): Based on weight once daily for 10 days
- Community outbreak: Based on weight once daily for up to 6 weeks
- Renally impaired patients (creatinine clearance 10-30 mL/min): Reduce to 75 mg once every other day or 30 mg once daily

Table 1: Treatment and Prophylaxis Dosing of Oral TAMIFLU for Influenza for Patients 1 Year of Age and Older Based on Body Weight

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Weight (lbs)</th>
<th>Treatment Dosing for 5 days</th>
<th>Prophylaxis Dosing for 10 days</th>
<th>Volume of Oral Suspension (6 mg/mL) for each Dose*</th>
<th>Number of Bottles of Oral Suspension to Dispense</th>
<th>Number of Capsules and Strength to Dispense</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 kg or less</td>
<td>33 lbs or less</td>
<td>30 mg twice daily</td>
<td>30 mg once daily</td>
<td>5 mL</td>
<td>1 bottle</td>
<td>10 Capsules 30 mg</td>
</tr>
<tr>
<td>16 kg thru 23 kg</td>
<td>34 lbs thru 51 lbs</td>
<td>45 mg twice daily</td>
<td>45 mg once daily</td>
<td>7.5 mL</td>
<td>2 bottles</td>
<td>10 Capsules 45 mg</td>
</tr>
<tr>
<td>24 kg thru 40 kg</td>
<td>52 lbs thru 88 lbs</td>
<td>60 mg twice daily</td>
<td>60 mg once daily</td>
<td>10 mL</td>
<td>2 bottles</td>
<td>20 Capsules 30 mg</td>
</tr>
<tr>
<td>41 kg or more</td>
<td>89 lbs or more</td>
<td>75 mg twice daily</td>
<td>75 mg once daily</td>
<td>12.5 mL</td>
<td>3 bottles</td>
<td>10 Capsules 75 mg</td>
</tr>
</tbody>
</table>

- How Supplied: Capsules: 30-mg capsules, 45-mg capsules, and 75-mg capsules; Oral Suspension: 6 mg/mL

- Storage: Store the capsules at 25ºC (77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF) [See USP Controlled Room Temperature]. Store dry powder at 25ºC (77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF) [See USP Controlled Room Temperature]. Store constituted suspension under refrigeration for up to 17 days at 2º to 8ºC (36º to 46ºF). Do not freeze. Alternatively, store constituted suspension for up to 10 days at 25ºC (77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF) [See USP Controlled Room Temperature].

2 METHODS AND MATERIALS REVIEWED

DMEPA searched the FDA AERS database for Tamiflu medication error reports. We also reviewed the proposed Tamiflu insert labeling submitted by the Applicant.
2.1 SELECTION OF MEDICATION ERROR CASES

We searched the FDA Adverse Event Reporting System (AERS) database using the strategy listed in Table 1. Since the last label revision occurred on March 21, 2011, our AERS search was initiated using this date to present date.

<table>
<thead>
<tr>
<th>Table 1: AERS Search Strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
</tr>
<tr>
<td>Drug Names</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>MedDRA Search Strategy</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

The AERS database search identified 91 reports. Duplicates were merged into a single case. The NCC MERP Taxonomy of Medication Errors was used to code the type and factors contributing to the errors when sufficient information was provided by the reporter. After individual review, 83 reports were not included in the final analysis for the following reasons:

- Foreign cases involving:
  - Adverse drug reaction unrelated to medication error
  - Accidental ingestion
  - Overdoses (causes not reported, outcomes include rash, increased body temperature, laughing improperly, urticaria, fatigue, malaise, filmy vision, nausea and diarrhea)
  - Expired drug use (causes and outcomes not reported)
  - Wrong patient (causes and outcomes not reported)
  - Wrong technique (causes included not adding water to the powder; outcomes not reported)

- U.S. cases involving:
  - Accidental overdose
  - Expired drug use (causes and outcomes not reported)

---

Dose omissions (causes and outcomes not reported)
- No medication error reported
- Product quality issues from consumers complaining of the bitter taste of the reconstituted suspension resulting in patients vomiting

2.2 LABELS AND LABELING
Using the principals of human factors and Failure Mode and Effects Analysis, along with post marketing medication error data, the Division of Medication Error Prevention and Analysis (DMEPA) evaluated the following:
- Insert Labeling submitted June 21, 2012

2.3 PREVIOUSLY COMPLETED REVIEWS
DMEPA previously reviewed the proprietary name (OSE RCM # 00-0248, dated December 7, 2000), the labels and labeling (OSE RCM # 2010-2272, dated March 10, 2011), completed a postmarketing safety review (OSE RCM # 06-0158, dated September 1, 2006), attended a Type A Meeting (OSE RCM # 2008-1447, dated September 22, 2008), completed a Usability Study Protocol Review (OSE RCM # 2011-3176, dated November 2, 2011), and a Protocol Review (OSE RCM # 2011-3280, dated October 4, 2011). Thus, we reviewed them to ensure all of our recommendations were implemented. Our evaluation found that all of our recommendations were implemented.

3 MEDICATION ERROR RISK ASSESSMENT
The following sections describe the results of our AERS search and the risk assessment of the Tamiflu product design as well as the associated labels and labeling.

3.1 MEDICATION ERROR CASES
Following exclusions as described in section 2.1, eight Tamiflu medication error cases remained for our detailed analysis. Duplicates were merged into a single case. The NCC MERP Taxonomy of Medication Errors was used to code the type and factors contributing to the errors when sufficient information was provided by the reporter. Figure 1 provides a stratification of the number of cases included in the review by type of error.

---


Wrong Frequency:
- ISR # 7363894 (March 21, 2011): Patient received therapy with oral Tamiflu at a dose of 2 mL twice daily. The report stated that the pharmacy had dispensed the medication and labeled it with the instructions to be administered four times a day instead of two times a day as prescribed. The patient had only taken two doses. Outcomes were not reported.

Overdose:
- ISR # 7377866 (March 28, 2011): A patient was prescribed Tamiflu 75 mg oral capsules twice daily for five days. However, the patient took 2 capsules, equaling 150 mg twice daily for 2 days. Cause and outcomes were not reported.
- ISR # 7386600 (March 31, 2011): A patient started therapy with Tamiflu Oral Suspension with a dose of 120 mg twice daily. The pharmacist stated that the patient was receiving twice the dose prescribed. The patient was supposed to take 60 mg twice a day and instead, the patient took 120 mg twice a day. The reporter stated the cause of the error was pharmacist error. Outcomes were not reported.
- ISR # 7402740 (April 8, 2011): A patient started treatment with Tamiflu “15/mL” twice daily. The mother reported that on the same day that the patient received the drug, the pharmacy made a mistake on the amount her son was supposed to receive. Her son received 3 doses of Tamiflu at twice the recommended amount. The patient experienced diarrhea.
- ISR # 7568266 (June 23, 2011): A patient was prescribed Tamiflu 12 mg/mL Oral Suspension at a dose of 3.75 mL twice a day. The prescription was filled in error as Tamiflu 12 mg/mL suspension teaspoonfuls twice a day. The patient
received one 3.75 teaspoonful dose on the first day of therapy and then two 3.75 teaspoonful doses the next day. The patient experienced nausea and vomiting.

- **ISR # 8038013 (January 11, 2012):** A physician prescribed Tamiflu 45 mg/day for a patient and the pharmacy filled the prescription from an older Tamiflu suspension with a concentration of 12 mg/mL. The patient was given oral Tamiflu 89 mg per 1.5 teaspoonfuls twice a day for 2 days. The pharmacist stated this was overdose because she received more than the typical adult dose and was referred to the poison center for further assistance. Outcomes were not reported.

- **ISR # 8238122 (March 27, 2012):** A patient was prescribed Tamiflu and the physician originally wrote the order for the 12 mg/mL concentration. When he got to the pharmacy he was told that it was the old formulation and that they would convert it to the new formulation. However the pharmacist did not call the physician to verify dosing. The pharmacy dispensed 4 bottles of Tamiflu and the label read as 6 mg/mL to be given 20 mL twice daily. This meant the total daily dose was 40 mL. On the same day, the child took her first dose. The next day, she vomited and continued to vomit for two days. On the third day, the patient’s fever got worse and went up to 104.0 degrees. It was reported that the Tamiflu was not working. She was given Acetaminophen and Ibuprofen staggered every 2 hours and her fever came down to 99.0 degrees. The fever eventually resolved.

**Labeling Complaint:**

- **ISR # 7671529 (August 9, 2011):** The reporter stated that the Tamiflu package insert is confusing. In the table titled, “Table 1: Treatment and Prophylaxis Dosing of Oral Tamiflu for Influenza for Patients 1 Year of Age and Older Based on Body Weight”, the table presents a weight-based dosing chart from 15 kg to 41 kg. Further in the package insert, it states standard dosing for patients 13 years of age or older is 75 mg once daily for prophylaxis and twice daily for treatment. It is unclear what correct dosing should be for patients who are 13 years or older and weigh under 41 kg. The reporter spoke with a Genetech representative and was told that any patient over the age of 13 should receive adult dosing. The reporter stated that the title of Table 1 should read "For patients age 1 to 12".

After review of the proposed insert labeling, we find that the Applicant has made revisions to the Dosage and Administration section that may mitigate the above mentioned medication errors, such as revising the title of Table 1. However, we have further recommendations that may help eliminate the risk of the above mentioned medication errors from occurring.

### 3.2 Insert Labeling Risk Assessment

A review of the insert labeling identified the following inconsistencies within the package insert labeling:

- Table 1 of the Dosage and Administration section
  - In the title, the word “of” in (5 day of dosing) does not seem to be grammatically correct.
4 CONCLUSIONS

DMEPA concludes that the proposed insert labeling is unacceptable due to inconsistencies in Table 1 of the Dosage and Administration section.

5 RECOMMENDATIONS

Based on this review, DMEPA recommends the following be implemented prior to approval of this NDA supplement:

A. Insert Labeling
   • Table 1 of the Dosage and Administration section
      o In the title of Table 1, remove the word after (5 day) to make it grammatically correct.
      o The table has weight represented in terms of both kilograms and pounds. The preferred practice in medicine is to use the metric system to express weight, volume, and units. There are exceptions to this practice, such as over-the-counter (OTC) product labeling. Having both kilograms and pounds for a prescription drug product can be confusing to prescribers. A practitioner could misread the weight columns and select the wrong dose for a patient. Removing all references to dosing in pounds will help alleviate confusion with associating a weight to a dose.
      o The Treatment and Prophylaxis dosing columns do not have the frequency in the title. Incorporating a frequency into the title or header can help to further differentiate the treatment and prophylaxis dosing. This may help prevent prescribing errors.

If you have further questions or need clarifications, please contact Danyal Chaudhry, project manager, at 301-796-3813.
APPENDICES

APPENDIX A. DATABASE DESCRIPTIONS

Adverse Event Reporting System (AERS)

The Adverse Event Reporting System (AERS) is a computerized information database designed to support the FDA's post-marketing safety surveillance program for drug and therapeutic biologic products. The FDA uses AERS to monitor adverse events and medication errors that might occur with these marketed products. The structure of AERS complies with the international safety reporting guidance (ICH E2B) issued by the International Conference on Harmonisation. Adverse events in AERS are coded to terms in the Medical Dictionary for Regulatory Activities terminology (MedDRA).

AERS data do have limitations. First, there is no certainty that the reported event was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. Further, FDA does not receive all adverse event reports that occur with a product. Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event. Therefore, AERS cannot be used to calculate the incidence of an adverse event in the U.S. population.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MORGAN A WALKER
11/15/2012

JAMIE C WILKINS PARKER
11/16/2012

SCOTT M DALLAS
11/16/2012
## RPM FILING REVIEW
(Including Memo of Filing Meeting)
To be completed for all new NDAs, BLAs, and Efficacy Supplements [except SE8 (labeling change with clinical data) and SE9 (manufacturing change with clinical data)]

<table>
<thead>
<tr>
<th>Application Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA # 21087</td>
</tr>
<tr>
<td>NDA # 21246</td>
</tr>
<tr>
<td>BLA#</td>
</tr>
<tr>
<td>NDA Supplement #: S- 062</td>
</tr>
<tr>
<td>NDA Supplement #: S-045</td>
</tr>
<tr>
<td>BLA Supplement #</td>
</tr>
<tr>
<td>Efficacy Supplement Type SE-5 and pediatric</td>
</tr>
</tbody>
</table>

Proprietary Name: TAMIFLU
Established/Proper Name: oseltamivir phosphate
Dosage Form: capsules; oral suspension
Strengths: 30, 45 and 75 mg capsules; 6 mg/mL (powder for oral suspension)

Applicant: Hoffmann-La Roche, Inc.
Agent for Applicant (if applicable): Genentech, Inc.

Date of Application: June 21, 2012
Date of Receipt: June 21, 2012 (NDA 21-087/S-062 received June 22, 2012)
Date clock started after UN: N/A

PDUFA Goal Date: December 21, 2012
Action Goal Date (if different): 
Filing Date: August 20, 2012
Date of Filing Meeting: July 31, 2012

Chemical Classification: (1,2,3 etc.) (original NDAs only) N/A

Proposed indication(s)/Proposed change(s): expanded patient population to include treatment for under one year of age

Type of Original NDA: 
  AND (if applicable) 
Type of NDA Supplement:


Review Classification:
If the application includes a complete response to pediatric WR, review classification is Priority.
If a tropical disease priority review voucher was submitted, review classification is Priority.

Resubmission after withdrawal? [ ] Resubmission after refuse to file? [ ]

Part 3 Combination Product? [ ]
If yes, contact the Office of Combination Products (OCP) and copy them on all Inter-Center consults

[ ] Convenience kit/Co-package
[ ] Pre-filled drug delivery device/system (syringe, patch, etc.)
[ ] Pre-filled biologic delivery device/system (syringe, patch, etc.)
[ ] Device coated/impregnated/combined with drug
[ ] Device coated/impregnated/combined with biologic
[ ] Separate products requiring cross-labeling
[ ] Drug/Biologic
[ ] Possible combination based on cross-labeling of separate products
[ ] Other (drug/device/biological product)
<table>
<thead>
<tr>
<th>Goal Dates/Product Names/Classification Properties</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDUFA and Action Goal dates correct in tracking system?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>If no, ask the document room staff to correct them immediately. These are the dates used for calculating inspection dates.</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are the proprietary, established/proper, and applicant names correct in tracking system?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>If no, ask the document room staff to make the corrections. Also, ask the document room staff to add the established/proper name to the supporting IND(s) if not already entered into tracking system.</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the review priority (S or P) and all appropriate classifications/properties entered into tracking system (e.g., chemical classification, combination product classification, 505(b)(2), orphan drug)? For NDAs/NDA supplements, check the New Application and New Supplement Notification Checklists for a list of all classifications/properties at: <a href="http://inside.fda.gov/9003/CDER/OfficeofBusinessProcessSupport/ucm163969.htm">http://inside.fda.gov/9003/CDER/OfficeofBusinessProcessSupport/ucm163969.htm</a></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>If no, ask the document room staff to make the appropriate entries.</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Application Integrity Policy</td>
<td>YES</td>
<td>NO</td>
<td>NA</td>
<td>Comment</td>
</tr>
<tr>
<td>Is the application affected by the Application Integrity Policy (AIP)? Check the AIP list at: <a href="http://www.fda.gov/ICECI/EnforcementActions/ApplicationIntegrityPolicy/default.htm">http://www.fda.gov/ICECI/EnforcementActions/ApplicationIntegrityPolicy/default.htm</a></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>If yes, explain in comment column.</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If affected by AIP, has OC/OMPQ been notified of the submission? <em>If yes, date notified:</em> X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>User Fees</td>
<td>YES</td>
<td>NO</td>
<td>NA</td>
<td>Comment</td>
</tr>
<tr>
<td>Is Form 3397 (User Fee Cover Sheet) included with authorized signature?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
If a user fee is required and it has not been paid (and it is not exempted or waived), the application is unacceptable for filing following a 5-day grace period. Review stops. Send Unacceptable for Filing (UN) letter and contact user fee staff.

Payment for this application:
- [ ] Paid
- [ ] Exempt (orphan, government)
- [ ] Waived (e.g., small business, public health)
- [ ] Not required

If the firm is in arrears for other fees (regardless of whether a user fee has been paid for this application), the application is unacceptable for filing (5-day grace period does not apply). Review stops. Send UN letter and contact the user fee staff.

Payment of other user fees:
- [ ] Not in arrears
- [ ] In arrears

<table>
<thead>
<tr>
<th>505(b)(2) (NDAs/NDA Efficacy Supplements only)</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is the application for a duplicate of a listed drug and eligible for approval under section 505(j) as an ANDA?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the application for a duplicate of a listed drug whose only difference is that the extent to which the active ingredient(s) is absorbed or otherwise made available to the site of action is less than that of the reference listed drug (RLD)? [see 21 CFR 314.54(b)(1)].</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the application for a duplicate of a listed drug whose only difference is that the rate at which the proposed product’s active ingredient(s) is absorbed or made available to the site of action is unintentionally less than that of the listed drug [see 21 CFR 314.54(b)(2)]?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If you answered yes to any of the above questions, the application may be refused for filing under 21 CFR 314.101(d)(9). Contact the (b)(2) review staff in the Immediate Office of New Drugs.

Is there unexpired exclusivity on the active moiety (e.g., 5-year, 3-year, orphan, or pediatric exclusivity)?
Check the Electronic Orange Book at: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm

If yes, please list below:

<table>
<thead>
<tr>
<th>Application No.</th>
<th>Drug Name</th>
<th>Exclusivity Code</th>
<th>Exclusivity Expiration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If there is unexpired, 3-year exclusivity remaining on the active moiety for the proposed drug product, a 505(b)(2) application cannot be submitted until the period of exclusivity expires (unless the applicant provides paragraph IV patent certification; then an application can be submitted four years after the date of approval). Pediatric exclusivity will extend both of the timeframes in this provision by 6 months. 21 CFR 314.108(b)(2). Unexpired, 3-year exclusivity will only block the approval, not the submission of a 505(b)(2) application.

<table>
<thead>
<tr>
<th>Exclusivity</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does another product (same active moiety) have orphan exclusivity for the same indication? Check the Orphan Drug Designations and Approvals list at: <a href="http://www.accessdata.fda.gov/scripts/opdlisting/opd/index.cfm">http://www.accessdata.fda.gov/scripts/opdlisting/opd/index.cfm</a></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Version: 4/17/12
Reference ID: 3181074
If another product has orphan exclusivity, is the product considered to be the same product according to the orphan drug definition of sameness [see 21 CFR 316.3(b)(13)]? X

If yes, consult the Director, Division of Regulatory Policy II, Office of Regulatory Policy

Has the applicant requested 5-year or 3-year Waxman-Hatch exclusivity? (NDAs/NDA efficacy supplements only) X

If yes, # years requested:

Note: An applicant can receive exclusivity without requesting it; therefore, requesting exclusivity is not required.

Is the proposed product a single enantiomer of a racemic drug previously approved for a different therapeutic use (NDAs only)? X

If yes, did the applicant: (a) elect to have the single enantiomer (contained as an active ingredient) not be considered the same active ingredient as that contained in an already approved racemic drug, and/or (b): request exclusivity pursuant to section 505(u) of the Act (per FDAAA Section 1113)? X

If yes, contact Mary Ann Holovac, Director of Drug Information, OGD/DLPS/LRB.

### Format and Content

Do not check mixed submission if the only electronic component is the content of labeling (COL).

<table>
<thead>
<tr>
<th>All paper (except for COL)</th>
<th>All electronic</th>
<th>Mixed (paper/electronic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTD</td>
<td>Non-CTD</td>
<td>Mixed (CTD/non-CTD)</td>
</tr>
</tbody>
</table>

If mixed (paper/electronic) submission, which parts of the application are submitted in electronic format?

<table>
<thead>
<tr>
<th>Overall Format/Content</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>If electronic submission, does it follow the eCTD guidance?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If not, explain (e.g., waiver granted).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index: Does the submission contain an accurate comprehensive index?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the submission complete as required under 21 CFR 314.50 (NDAs/NDA efficacy supplements) or under 21 CFR 601.2 (BLAs/BLA efficacy supplements) including:</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

<table>
<thead>
<tr>
<th><strong>Forms and Certifications</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic forms and certifications with electronic signatures (scanned, digital, or electronic – similar to DARRTS, e.g., /s/) are acceptable. Otherwise, <strong>paper</strong> forms and certifications with hand-written signatures must be included. <strong>Forms</strong> include: user fee cover sheet (3397), application form (356h), patent information (3542a), financial disclosure (3454/3455), and clinical trials (3674); <strong>Certifications</strong> include: debarment certification, patent certification(s), field copy certification, and pediatric certification.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Application Form</strong></th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is form FDA 356h included with authorized signature per 21 CFR 314.50(a)?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>If foreign applicant, a U.S. agent must sign the form [see 21 CFR 314.50(a)(5)].</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are all establishments and their registration numbers listed on the form/attached to the form?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Patent Information</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(NDAs/NDA efficacy supplements only)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Patent Information</strong></th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is patent information submitted on form FDA 3542a per 21 CFR 314.53(c)?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Financial Disclosure</strong></th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Are financial disclosure forms FDA 3454 and/or 3455 included with authorized signature per 21 CFR 54.4(a)(1) and (3)?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Forms must be signed by the APPLICANT, not an Agent [see 21 CFR 54.2(g)].</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Note: Financial disclosure is required for bioequivalence studies that are the basis for approval.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Clinical Trials Database</strong></th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is form FDA 3674 included with authorized signature?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>If yes, ensure that the application is also coded with the supporting document category, “Form 3674.”</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>If no, ensure that language requesting submission of the form is included in the acknowledgement letter sent to the applicant</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Debarment Certification</strong></th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is a correctly worded Debarment Certification included with authorized signature?</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Certification** is not required for supplements if submitted in the original application; if foreign applicant, both the applicant and the U.S. Agent must sign the certification [per Guidance for Industry: Submitting Debarment Certifications].

*Note:* Debarment Certification should use wording in FD&C Act Section 306(k)(1) i.e., “[Name of applicant] hereby certifies that it did not and will not use in any capacity the services of any person debarred under section 306 of the Federal Food, Drug, and Cosmetic Act in connection with this application.” Applicant may not use wording such as, “To the best of my knowledge…”

<table>
<thead>
<tr>
<th>Field Copy Certification (NDAs/NDA efficacy supplements only)</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>For paper submissions only: Is a Field Copy Certification (that it is a true copy of the CMC technical section) included?</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Field Copy Certification is not needed if there is no CMC technical section or if this is an electronic submission (the Field Office has access to the EDR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If maroon field copy jackets from foreign applicants are received, return them to CDR for delivery to the appropriate field office.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Controlled Substance/Product with Abuse Potential</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>For NMEs: Is an Abuse Liability Assessment, including a proposal for scheduling, submitted per 21 CFR 314.50(d)(5)(vii)?</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>If yes, date consult sent to the Controlled Substance Staff:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For non-NMEs: Date of consult sent to Controlled Substance Staff:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pediatrics</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>PREA</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Does the application trigger PREA?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If yes, notify PeRC RPM (PeRC meeting is required)²</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Note:* NDAs/BLAs/efficacy supplements for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration trigger PREA. All waiver & deferral requests, pediatric plans, and pediatric assessment studies must be reviewed by PeRC prior to approval of the application/supplement.

If the application triggers PREA, are the required pediatric assessment studies or a full waiver of pediatric studies included? | | | | X |

² [http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/PediatricandMaternalHealthStaff/ucm027829.htm](http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/PediatricandMaternalHealthStaff/ucm027829.htm)
If studies or full waiver not included, is a request for full waiver of pediatric studies OR a request for partial waiver and/or deferral with a pediatric plan included?

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>If no, request in 74-day letter</strong></td>
<td></td>
</tr>
<tr>
<td>If a request for full waiver/partial waiver/deferral is included, does the application contain the certification(s) required by FDCA Section 505B(a)(3) and (4)?</td>
<td>X</td>
</tr>
<tr>
<td><strong>If no, request in 74-day letter</strong></td>
<td></td>
</tr>
<tr>
<td>BPCA (NDAs/NDA efficacy supplements only):</td>
<td></td>
</tr>
<tr>
<td>Is this submission a complete response to a pediatric Written Request?</td>
<td></td>
</tr>
<tr>
<td>If yes, notify Pediatric Exclusivity Board RPM (pediatric exclusivity determination is required)</td>
<td></td>
</tr>
<tr>
<td><strong>Proprietary Name</strong></td>
<td>YES</td>
</tr>
<tr>
<td>Is a proposed proprietary name submitted?</td>
<td>X</td>
</tr>
<tr>
<td>If yes, ensure that the application is also coded with the supporting document category, “Proprietary Name/Request for Review.”</td>
<td></td>
</tr>
<tr>
<td><strong>REMS</strong></td>
<td>YES</td>
</tr>
<tr>
<td>Is a REMS submitted?</td>
<td>X</td>
</tr>
<tr>
<td>If yes, send consult to OSE/DRISK and notify OC/OSI/DSC/PMSB via the CDER OSI RMP mailbox</td>
<td></td>
</tr>
<tr>
<td><strong>Prescription Labeling</strong></td>
<td>Not applicable</td>
</tr>
<tr>
<td>Check all types of labeling submitted.</td>
<td></td>
</tr>
<tr>
<td>Package Insert (PI)</td>
<td></td>
</tr>
<tr>
<td>Patient Package Insert (PPI)</td>
<td></td>
</tr>
<tr>
<td>Instructions for Use (IFU)</td>
<td></td>
</tr>
<tr>
<td>Medication Guide (MedGuide)</td>
<td></td>
</tr>
<tr>
<td>Carton labels</td>
<td></td>
</tr>
<tr>
<td>Immediate container labels</td>
<td></td>
</tr>
<tr>
<td>Diluent</td>
<td></td>
</tr>
<tr>
<td>Other (specify)</td>
<td></td>
</tr>
<tr>
<td><strong>Is Electronic Content of Labeling (COL) submitted in SPL format?</strong></td>
<td>X</td>
</tr>
<tr>
<td><strong>If no, request applicant to submit SPL before the filing date.</strong></td>
<td></td>
</tr>
<tr>
<td>Is the PI submitted in PLR format?</td>
<td>X</td>
</tr>
</tbody>
</table>

3 http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/PediatricandMaternalHealthStaff/ucm027837.htm
If PI not submitted in PLR format, was a waiver or deferral requested before the application was received or in the submission? **If requested before application was submitted**, what is the status of the request?

<table>
<thead>
<tr>
<th>If no waiver or deferral, request applicant to submit labeling in PLR format before the filing date.</th>
</tr>
</thead>
<tbody>
<tr>
<td>All labeling (PI, PPI, MedGuide, IFU, carton and immediate container labels) consulted to OPDP?</td>
</tr>
<tr>
<td>MedGuide, PPI, IFU (plus PI) consulted to Patient Labeling Team? (send WORD version if available)</td>
</tr>
<tr>
<td>Carton and immediate container labels, PI, PPI sent to OSE/DMEPA and appropriate CMC review office (OBP or ONDQA)?</td>
</tr>
</tbody>
</table>

**OTC Labeling**

Check all types of labeling submitted.

- [x] Not Applicable

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is electronic content of labeling (COL) submitted?</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**If no, request in 74-day letter.**

- Are annotated specifications submitted for all stock keeping units (SKUs)?
- If yes, specify consult(s) and date(s) sent:
- Meeting Minutes/SPAs
- End-of Phase 2 meeting(s)?
- Date(s):
- If yes, distribute minutes before filing meeting

<table>
<thead>
<tr>
<th>Other Consults</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Are additional consults needed? (e.g., IFU to CDRH; QT study report to QT Interdisciplinary Review Team)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Version: 4/17/12
Reference ID: 3181074
<table>
<thead>
<tr>
<th>Question</th>
<th>Yes/No</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-NDA/Pre-BLA/Pre-Supplement meeting(s)?</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Date(s):</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>If yes, distribute minutes before filing meeting</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any Special Protocol Assessments (SPAs)?</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Date(s):</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>If yes, distribute letter and/or relevant minutes before filing meeting</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ATTACHMENT

MEMO OF FILING MEETING

DATE: July 31, 2012

NDA/Supp #: 21087/S-062 and 21246/S-045

PROPRIETARY NAME: TAMIFLU

ESTABLISHED/PROPER NAME: oseltamivir phosphate

DOSAGE FORM/STRENGTH: 30, 45, 75 mg capsules and 6mg/mL powder for oral suspension

APPLICANT: Hoffmann-La Roche, Inc.

PROPOSED INDICATION(S)/PROPOSED CHANGE(S): Expands the patient population for the treatment of influenza in infants with a post conceptual age of [8] weeks to one year of age

BACKGROUND: Tamiflu is currently approved under NDA 21087 (capsules) and NDA 21246 (powder for oral suspension). Tamiflu is indicated for (1) treatment of uncomplicated acute illness due to influenza infection in patients 1 year and older who have been symptomatic for no more than 2 days and (2) prophylaxis of influenza in patients 1 year and older.

These supplements provide two pivotal pediatric studies for review (1) CASG114 entitled “A Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu®) for the Treatment of Children Less than 24 Months of Age with Confirmed Influenza Infection” and (2) WP22849 entitled “An Open-Label, Prospective, Pharmacokinetic/Pharmacodynamic, and Safety Evaluation of Oseltamivir (Tamiflu®) in the Treatment of Infants 0 to < 12 Months of Age with Confirmed Influenza Infection.”

REVIEW TEAM:

<table>
<thead>
<tr>
<th>Discipline/Organization</th>
<th>Names</th>
<th>Present at filing meeting? (Y or N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regulatory Project Management</td>
<td>RPM: Elizabeth Thompson</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td>CPMS/TL: Karen Winestock</td>
<td>Y</td>
</tr>
<tr>
<td>Cross-Discipline Team Leader (CDTL)</td>
<td>Linda Lewis</td>
<td>Y</td>
</tr>
<tr>
<td>Clinical</td>
<td>Reviewer: Tafadzwa Vargas-Kasambira</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td>TL: Linda Lewis</td>
<td>Y</td>
</tr>
<tr>
<td>Social Scientist Review (for OTC products)</td>
<td>Reviewer: N/A</td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>TL:</td>
<td>Reviewer:</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td><strong>OTC Labeling Review (for OTC products)</strong></td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Clinical Microbiology (for antimicrobial products)</strong></td>
<td></td>
<td>Damon Deming</td>
</tr>
<tr>
<td><strong>Clinical Pharmacology</strong></td>
<td></td>
<td>Jules O’Rear</td>
</tr>
<tr>
<td><strong>Clinical Pharmacology</strong></td>
<td></td>
<td>Jenny Zheng</td>
</tr>
<tr>
<td><strong>Biostatistics</strong></td>
<td></td>
<td>Shirley Seo</td>
</tr>
<tr>
<td><strong>Nonclinical (Pharmacology/Toxicology)</strong></td>
<td>N/A</td>
<td>Ita Yuen</td>
</tr>
<tr>
<td><strong>Statistics (carcinogenicity)</strong></td>
<td>N/A</td>
<td>Hanan Ghantous</td>
</tr>
<tr>
<td><strong>Immunogenicity (assay/assay validation) (for BLAs/BLA efficacy supplements)</strong></td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Product Quality (CMC)</strong></td>
<td>N/A</td>
<td>Steve Miller</td>
</tr>
<tr>
<td><strong>Quality Microbiology (for sterile products)</strong></td>
<td>N/A</td>
<td>Tom Oliver</td>
</tr>
<tr>
<td><strong>CMC Labeling Review</strong></td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Facility Review/Inspection</strong></td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>OSE/DMEPA (proprietary name)</strong></td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>OSE/DRISK (REMS)</td>
<td>Reviewer: N/A</td>
<td></td>
</tr>
<tr>
<td>------------------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td>TL: N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OC/OSI/DSC/PMSB (REMS)</td>
<td>Reviewer: N/A</td>
<td></td>
</tr>
<tr>
<td>TL: N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bioresearch Monitoring (OSI)</td>
<td>Reviewer: N/A</td>
<td></td>
</tr>
<tr>
<td>TL: N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Controlled Substance Staff (CSS)</td>
<td>Reviewer: N/A</td>
<td></td>
</tr>
<tr>
<td>TL: N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Other reviewers        | DMPP Reviewer: Latonia Ford  
DMPP TL: Barbara Fuller  
DMEPA Reviewer: Morgan Walker  
DMEPA TL: Jamie Wilkins-Parker  
DDTCP Reviewer: Kemi Asante  
DPP Reviewer: Jessica Fox  
DDTCP/DPP TL: Olga Salis |
| Other attendees        | Jee Eun Lee, Pharmacometrics Reviewer  
Yaning Wang, Pharmacometrics TL |

**FILING MEETING DISCUSSION:**

**GENERAL**

- 505(b)(2) filing issues?  
  - Not Applicable  
  - [ ] YES  
  - [ ] NO

  **If yes, list issues:**

- Per reviewers, are all parts in English or English translation?  
  - [ ] YES  
  - [ ] NO

  **If no, explain:**

- Electronic Submission comments  
  - [ ] Not Applicable  
  - [ ] File  
  - [ ] Refuse to File

**CLINICAL**

- Comments: To be included in filing letter  
  - Review issues for 74-day letter

- Clinical study site(s) inspections(s) needed?  
  - [ ] YES
<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>If no, explain:</td>
<td></td>
<td>☒</td>
<td></td>
</tr>
<tr>
<td>- Advisory Committee Meeting needed?</td>
<td>☐</td>
<td>☒</td>
<td></td>
</tr>
<tr>
<td>Comments:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If no, for an original NME or BLA application, include the reason.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>For example:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- this drug/biologic is not the first in its class</td>
<td>☐</td>
<td>☒</td>
<td></td>
</tr>
<tr>
<td>- the clinical study design was acceptable</td>
<td>☐</td>
<td>☒</td>
<td></td>
</tr>
<tr>
<td>- the application did not raise significant safety or efficacy issues</td>
<td>☐</td>
<td>☒</td>
<td></td>
</tr>
<tr>
<td>- the application did not raise significant public health questions on</td>
<td>☐</td>
<td>☒</td>
<td></td>
</tr>
<tr>
<td>the role of the drug/biologic in the diagnosis, cure, mitigation,</td>
<td>☐</td>
<td>☒</td>
<td></td>
</tr>
<tr>
<td>treatment or prevention of a disease</td>
<td>☐</td>
<td>☒</td>
<td></td>
</tr>
<tr>
<td>Reason:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Abuse Liability/Potential</td>
<td>☒</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Comments:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If the application is affected by the AIP, has the division made a</td>
<td>☒</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>recommendation regarding whether or not an exception to the AIP should</td>
<td>☐</td>
<td>☒</td>
<td></td>
</tr>
<tr>
<td>be granted to permit review based on medical necessity or public health</td>
<td>☒</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>significance?</td>
<td>☐</td>
<td>☒</td>
<td></td>
</tr>
<tr>
<td>Comments:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CLINICAL MICROBIOLOGY</td>
<td>☒</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Comments: No comments</td>
<td>☐</td>
<td>☒</td>
<td></td>
</tr>
<tr>
<td>CLINICAL PHARMACOLOGY</td>
<td>☒</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Comments: No comments</td>
<td>❏</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>- Clinical pharmacology study site(s) inspections(s) needed?</td>
<td>☒</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>BIOSTATISTICS</td>
<td>☒</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>Comments:</td>
<td>☐ Review issues for 74-day letter</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>----------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>NONCLINICAL</strong>&lt;br&gt;(PHARMACOLOGY/TOXICOLOGY)</td>
<td>☒ Not Applicable&lt;br&gt;☐ FILE&lt;br&gt;☐ REFUSE TO FILE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comments:</td>
<td>☐ Review issues for 74-day letter</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IMMUNOGENICITY (BLAs/BLA efficacy supplements only)</strong></td>
<td>☒ Not Applicable&lt;br&gt;☐ FILE&lt;br&gt;☐ REFUSE TO FILE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comments:</td>
<td>☐ Review issues for 74-day letter</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PRODUCT QUALITY (CMC)</strong></td>
<td>☐ Not Applicable&lt;br&gt;☐ FILE&lt;br&gt;☐ REFUSE TO FILE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comments:</td>
<td>☐ Review issues for 74-day letter</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Environmental Assessment</strong></td>
<td>☒ Not Applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Categorical exclusion for environmental assessment (EA) requested?</td>
<td>☒ YES&lt;br&gt;☐ NO</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>If no,</strong> was a complete EA submitted?</td>
<td>☒ YES&lt;br&gt;☐ NO</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>If EA submitted,</strong> consulted to EA officer (OPS)?</td>
<td>☒ YES&lt;br&gt;☐ NO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comments:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Quality Microbiology (for sterile products)</strong></td>
<td>☒ Not Applicable</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Was the Microbiology Team consulted for validation of sterilization? (NDAs/NDA supplements only)</td>
<td>☒ YES&lt;br&gt;☐ NO</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Facility Inspection

- Establishment(s) ready for inspection?  
  - □ YES  
  - □ NO  
- Establishment Evaluation Request (EER/TBP-EER) submitted to OMPQ?  
  - □ YES  
  - □ NO

**Comments:**

### Facility/Microbiology Review (BLAs only)

- Not Applicable  
  - □ FILE  
  - □ REFUSE TO FILE

**Comments:**

### CMC Labeling Review

**Comments:** No changes proposed

**Review issues for 74-day letter**

### REGULATORY PROJECT MANAGEMENT

**Signatory Authority:** Debbie Birnkrant, M.D.

**21st Century Review Milestones (see attached)** (listing review milestones in this document is optional):

**Comments:**

### REGULATORY CONCLUSIONS/DEFICIENCIES

- □ The application is unsuitable for filing. Explain why:
- ✗ The application, on its face, appears to be suitable for filing.

**Review Issues:**

- ✗ No review issues have been identified for the 74-day letter.
- □ Review issues have been identified for the 74-day letter.

**Review Classification:**

- □ Standard Review  
- ✗ Priority Review

**Version:** 4/17/12  
**Reference ID:** 3181074
# ACTIONS ITEMS

<table>
<thead>
<tr>
<th></th>
<th>Ensure that any updates to the review priority (S or P) and classifications/properties are entered into tracking system (e.g., chemical classification, combination product classification, 505(b)(2), orphan drug).</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>If RTF, notify everybody who already received a consult request, OSE PM, and Product Quality PM (to cancel EER/TBP-EER).</td>
</tr>
<tr>
<td></td>
<td>If filed, and the application is under AIP, prepare a letter either granting (for signature by Center Director) or denying (for signature by ODE Director) an exception for review.</td>
</tr>
<tr>
<td></td>
<td>BLA/BLA supplements: If filed, send 60-day filing letter</td>
</tr>
</tbody>
</table>
|   | If priority review:  
|   |   - notify sponsor in writing by day 60 (For BLAs/BLA supplements: include in 60-day filing letter; For NDAs/NDA supplements: see CST for choices)  
|   |   - notify OMPQ (so facility inspections can be scheduled earlier) |
|   | Send review issues/no review issues by day 74 |
|   | Conduct a PLR format labeling review and include labeling issues in the 74-day letter |
|   | BLA/BLA supplements: Send the Product Information Sheet to the product reviewer and the Facility Information Sheet to the facility reviewer for completion. Ensure that the completed forms are forwarded to the CDER RMS-BLA Superuser for data entry into RMS-BLA one month prior to taking an action [These sheets may be found in the CST eRoom at: http://eroom.fda.gov/eRoom/CDER2/CDERStandardLettersCommittee/0_1685f] |
|   | Other |
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ELIZABETH G THOMPSON
08/28/2012

KAREN D WINESTOCK
08/28/2012
REGULATORY PROJECT MANAGER
PHYSICIAN’S LABELING RULE (PLR) FORMAT REVIEW
OF THE PRESCRIBING INFORMATION

To be completed for all new NDAs, BLAs, Efficacy Supplements, and PLR Conversion Supplements

Application: NDA 21087/S-062 and NDA 21246/S-045

Application Type: Efficacy Supplement (Expand patient population to include patients with a post conceptual age of at least 4 weeks to less than 1 year of age)

Name of Drug: TAMIFLU (oseltamivir phosphate) 30, 45, 75 mg capsules and 6 mg/mL powder for oral suspension

Applicant: Hoffmann-La Roche, Inc.

Submission Date: June 21, 2012

Receipt Date: June 21, 2012 (NDA 21246) and June 22, 2012 (NDA 21087)

1.0 Regulatory History and Applicant’s Main Proposals
These supplements propose an expanded patient population for the treatment of influenza in infants with a post conceptual age of at least 4 weeks to 1 year of age.

2.0 Review of the Prescribing Information (PI)
This review is based on the applicant’s submitted Microsoft Word format of the PI. The applicant’s proposed PI was reviewed in accordance with the labeling format requirements listed in the “Selected Requirements for Prescribing Information (SRPI)” checklist (see the Appendix).

3.0 Conclusions/Recommendations
SRPI format deficiencies were identified in the review of this PI. For a list of these deficiencies see the Appendix.
4.0 Appendix

Selected Requirements of Prescribing Information (SRPI)

The Selected Requirement of Prescribing Information (SRPI) version 2 is a 48-item, drop-down checklist of critical format elements of the prescribing information (PI) based on labeling regulations (21 CFR 201.56 and 201.57) and labeling guidances.

Highlights (HL)

GENERAL FORMAT

YES 1. Highlights (HL) must be in two-column format, with ½ inch margins on all sides and in a minimum of 8-point font.

Comment:

NO 2. The length of HL must be less than or equal to one-half page (the HL Boxed Warning does not count against the one-half page requirement) unless a waiver has been granted in a previous submission (i.e., the application being reviewed is an efficacy supplement).

Instructions to complete this item: If the length of the HL is less than or equal to one-half page then select “YES” in the drop-down menu because this item meets the requirement. However, if HL is longer than one-half page:

➢ For the Filing Period (for RPMs)
  ▪ For efficacy supplements: If a waiver was previously granted, select “YES” in the drop-down menu because this item meets the requirement.
  ▪ For NDAs/BLAs and PLR conversions: Select “NO” in the drop-down menu because this item does not meet the requirement (deficiency). The RPM notifies the Cross-Discipline Team Leader (CDTL) of the excessive HL length and the CDTL determines if this deficiency is included in the 74-day or advice letter to the applicant.

➢ For the End-of Cycle Period (for SEALD reviewers)
  ▪ The SEALD reviewer documents (based on information received from the RPM) that a waiver has been previously granted or will be granted by the review division in the approval letter.

Comment:

YES 3. All headings in HL must be presented in the center of a horizontal line, in UPPER-CASE letters and bolded.

Comment:

YES 4. White space must be present before each major heading in HL.

Comment:

YES 5. Each summarized statement in HL must reference the section(s) or subsection(s) of the Full Prescribing Information (FPI) that contains more detailed information. The preferred format is the numerical identifier in parenthesis [e.g., (1.1)] at the end of each information summary (e.g. end of each bullet).

Comment:
6. Section headings are presented in the following order in HL:

<table>
<thead>
<tr>
<th>Section</th>
<th>Required/Optional</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Highlights Heading</td>
<td>Required</td>
</tr>
<tr>
<td>• Highlights Limitation Statement</td>
<td>Required</td>
</tr>
<tr>
<td>• Product Title</td>
<td>Required</td>
</tr>
<tr>
<td>• Initial U.S. Approval</td>
<td>Required</td>
</tr>
<tr>
<td>• Boxed Warning</td>
<td>Required if a Boxed Warning is in the FPI</td>
</tr>
<tr>
<td>• Recent Major Changes</td>
<td>Required for only certain changes to PI*</td>
</tr>
<tr>
<td>• Indications and Usage</td>
<td>Required</td>
</tr>
<tr>
<td>• Dosage and Administration</td>
<td>Required</td>
</tr>
<tr>
<td>• Dosage Forms and Strengths</td>
<td>Required</td>
</tr>
<tr>
<td>• Contraindications</td>
<td>Required (if no contraindications must state “None.”)</td>
</tr>
<tr>
<td>• Warnings and Precautions</td>
<td>Not required by regulation, but should be present</td>
</tr>
<tr>
<td>• Adverse Reactions</td>
<td>Required</td>
</tr>
<tr>
<td>• Drug Interactions</td>
<td>Optional</td>
</tr>
<tr>
<td>• Use in Specific Populations</td>
<td>Optional</td>
</tr>
<tr>
<td>• Patient Counseling Information Statement</td>
<td>Required</td>
</tr>
<tr>
<td>• Revision Date</td>
<td>Required</td>
</tr>
</tbody>
</table>

* RMC only applies to the Boxed Warning, Indications and Usage, Dosage and Administration, Contraindications, and Warnings and Precautions sections.

Comment:

7. A horizontal line must separate HL and Table of Contents (TOC).

Comment:

HIGHLIGHTS DETAILS

Highlights Heading

8. At the beginning of HL, the following heading must be **bolded** and appear in all **UPPER CASE** letters: “HIGHLIGHTS OF PRESCRIBING INFORMATION”.

Comment:

Highlights Limitation Statement

9. The **bolded** HL Limitation Statement must be on the line immediately beneath the HL heading and must state: “These highlights do not include all the information needed to use (insert name of drug product in UPPER CASE) safely and effectively. See full prescribing information for (insert name of drug product in UPPER CASE).”

Comment:

Product Title

10. Product title in HL must be **bolded**.

Comment:

Initial U.S. Approval

11. Initial U.S. Approval in HL must be placed immediately beneath the product title, **bolded**, and include the verbatim statement “Initial U.S. Approval:” followed by the 4-digit year.

Comment:
Selected Requirements of Prescribing Information (SRPI)

Boxed Warning

N/A 12. All text must be **bolded**.

*Comment:*

N/A 13. Must have a centered heading in UPPER-CASE, containing the word “**WARNING**” (even if more than one Warning, the term, “**WARNING**” and not “**WARNINGS**” should be used) and other words to identify the subject of the Warning (e.g., “**WARNING: SERIOUS INFECTIONS**”).

*Comment:*

N/A 14. Must always have the verbatim statement “**See full prescribing information for complete boxed warning.**” centered immediately beneath the heading.

*Comment:*

N/A 15. Must be limited in length to 20 lines (this does not include the heading and statement “**See full prescribing information for complete boxed warning.**”).

*Comment:*

N/A 16. Use sentence case for summary (combination of uppercase and lowercase letters typical of that used in a sentence).

*Comment:*

Recent Major Changes (RMC)

YES 17. Pertains to only the following five sections of the FPI: Boxed Warning, Indications and Usage, Dosage and Administration, Contraindications, and Warnings and Precautions.

*Comment:*

YES 18. Must be listed in the same order in HL as they appear in FPI.

*Comment:*

YES 19. Includes heading(s) and, if appropriate, subheading(s) of labeling section(s) affected by the recent major change, together with each section’s identifying number and date (month/year format) on which the change was incorporated in the PI (supplement approval date). For example, “Dosage and Administration, Coronary Stenting (2.2) --- 3/2012”.

*Comment:*

YES 20. Must list changes for at least one year after the supplement is approved and must be removed at the first printing subsequent to one year (e.g., no listing should be one year older than revision date).

*Comment:*

Indications and Usage

YES 21. If a product belongs to an established pharmacologic class, the following statement is required in the Indications and Usage section of HL: 

[[(Product) is a (name of class) indicated for (indication)].”

*Comment:*

Reference ID: 3181066
Selected Requirements of Prescribing Information (SRPI)

Dosage Forms and Strengths
YES 22. For a product that has several dosage forms, bulleted subheadings (e.g., capsules, tablets, injection, suspension) or tabular presentations of information is used.

Comment:

Contraindications
YES 23. All contraindications listed in the FPI must also be listed in HL or must include the statement “None” if no contraindications are known.

Comment:

N/A 24. Each contraindication is bulleted when there is more than one contraindication.

Comment:

Adverse Reactions
YES 25. For drug products other than vaccines, the verbatim bolded statement must be present: “To report SUSPECTED ADVERSE REACTIONS, contact (insert name of manufacturer) at (insert manufacturer’s U.S. phone number) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch”.

Comment:

Patient Counseling Information Statement
YES 26. Must include one of the following three bolded verbatim statements (without quotation marks):

If a product does not have FDA-approved patient labeling:
• “See 17 for PATIENT COUNSELING INFORMATION”

If a product has FDA-approved patient labeling:
• “See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.”
• “See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.”

Comment:

Revision Date
YES 27. Bolded revision date (i.e., “Revised: MM/YYYY or Month Year”) must be at the end of HL.

Comment:

Contents: Table of Contents (TOC)

GENERAL FORMAT
YES 28. A horizontal line must separate TOC from the FPI.

Comment:

YES 29. The following bolded heading in all UPPER CASE letters must appear at the beginning of TOC: “FULL PRESCRIBING INFORMATION: CONTENTS”.

Comment:
30. The section headings and subheadings (including title of the Boxed Warning) in the TOC must match the headings and subheadings in the FPI.

Comment:

N/A 31. The same title for the Boxed Warning that appears in the HL and FPI must also appear at the beginning of the TOC in UPPER-CASE letters and **bolded**.

Comment:

YES 32. All section headings must be **bolded** and in UPPER CASE.

Comment:

YES 33. All subsection headings must be indented, not bolded, and in title case.

Comment:

YES 34. When a section or subsection is omitted, the numbering does not change.

Comment:

YES 35. If a section or subsection from 201.56(d)(1) is omitted from the FPI and TOC, the heading “FULL PRESCRIBING INFORMATION: CONTENTS” must be followed by an asterisk and the following statement must appear at the end of TOC: “*Sections or subsections omitted from the Full Prescribing Information are not listed.”

Comment:

Full Prescribing Information (FPI)

GENERAL FORMAT

YES 36. The following heading must appear at the beginning of the FPI in UPPER CASE and **bolded**: “FULL PRESCRIBING INFORMATION”.

Comment:

YES 37. All section and subsection headings and numbers must be **bolded**.

Comment:

YES 38. The **bolded** section and subsection headings must be named and numbered in accordance with 21 CFR 201.56(d)(1) as noted below. If a section/subsection is omitted, the numbering does not change.

<table>
<thead>
<tr>
<th>Boxed Warning</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 INDICATIONS AND USAGE</td>
</tr>
<tr>
<td>2 DOSAGE AND ADMINISTRATION</td>
</tr>
<tr>
<td>3 DOSAGE FORMS AND STRENGTHS</td>
</tr>
<tr>
<td>4 CONTRAINDICATIONS</td>
</tr>
<tr>
<td>5 WARNINGS AND PRECAUTIONS</td>
</tr>
<tr>
<td>6 ADVERSE REACTIONS</td>
</tr>
<tr>
<td>7 DRUG INTERACTIONS</td>
</tr>
<tr>
<td>8 USE IN SPECIFIC POPULATIONS</td>
</tr>
<tr>
<td>8.1 Pregnancy</td>
</tr>
<tr>
<td>8.2 Labor and Delivery</td>
</tr>
<tr>
<td>8.3 Nursing Mothers</td>
</tr>
<tr>
<td>8.4 Pediatric Use</td>
</tr>
<tr>
<td>8.5 Geriatric Use</td>
</tr>
</tbody>
</table>
Selected Requirements of Prescribing Information (SRPI)

<table>
<thead>
<tr>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
</tr>
<tr>
<td>9.1</td>
</tr>
<tr>
<td>9.2</td>
</tr>
<tr>
<td>9.3</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>11</td>
</tr>
<tr>
<td>12</td>
</tr>
<tr>
<td>12.1</td>
</tr>
<tr>
<td>12.2</td>
</tr>
<tr>
<td>12.3</td>
</tr>
<tr>
<td>12.4</td>
</tr>
<tr>
<td>12.5</td>
</tr>
<tr>
<td>13</td>
</tr>
<tr>
<td>13.1</td>
</tr>
<tr>
<td>13.2</td>
</tr>
<tr>
<td>14</td>
</tr>
<tr>
<td>15</td>
</tr>
<tr>
<td>16</td>
</tr>
<tr>
<td>17</td>
</tr>
</tbody>
</table>

Comment:

39. FDA-approved patient labeling (e.g., Medication Guide, Patient Information, or Instructions for Use) must not be included as a subsection under Section 17 (Patient Counseling Information). All patient labeling must appear at the end of the PI upon approval.

Comment:

YES

40. The preferred presentation for cross-references in the FPI is the section heading (not subsection heading) followed by the numerical identifier in italics. For example, [see Warnings and Precautions (5.2)].

Comment:

YES

41. If RMCs are listed in HL, the corresponding new or modified text in the FPI sections or subsections must be marked with a vertical line on the left edge.

Comment:

FULL PRESCRIBING INFORMATION DETAILS

Boxed Warning

42. All text is **bolded**.

Comment:

N/A

43. Must have a heading in UPPER-CASE, containing the word “**WARNING**” (even if more than one Warning, the term, “**WARNING**” and not “**WARNINGS**” should be used) and other words to identify the subject of the Warning (e.g., “**WARNING: SERIOUS INFECTIONS**”).

Comment:

N/A

44. Use sentence case (combination of uppercase and lowercase letters typical of that used in a sentence) for the information in the Boxed Warning.

Comment:

Contraindications

N/A

45. If no Contraindications are known, this section must state “None”.

Reference ID: 3181066
Selected Requirements of Prescribing Information (SRPI)

Coment:

Adverse Reactions

46. When clinical trials adverse reactions data is included (typically in the “Clinical Trials Experience” subsection of Adverse Reactions), the following verbatim statement or appropriate modification should precede the presentation of adverse reactions:

“Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.”

Coment:

47. When postmarketing adverse reaction data is included (typically in the “Postmarketing Experience” subsection of Adverse Reactions), the following verbatim statement or appropriate modification should precede the presentation of adverse reactions:

“The following adverse reactions have been identified during post-approval use of (insert drug name). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.”

Comment:

Patient Counseling Information

48. Must reference any FDA-approved patient labeling, include the type of patient labeling, and use one of the following statements at the beginning of Section 17:

- “See FDA-approved patient labeling (Medication Guide)”
- “See FDA-approved patient labeling (Medication Guide and Instructions for Use)”
- “See FDA-approved patient labeling (Patient Information)”
- “See FDA-approved patient labeling (Instructions for Use)”
- “See FDA-approved patient labeling (Patient Information and Instructions for Use)”

Comment:
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ELIZABETH G THOMPSON
08/28/2012

KAREN D WINESTOCK
08/28/2012
DATE: August 24, 2012

TO: Associate Director
   International Operations Drug Group
   Division of Foreign Field Investigations

From: Sam H. Haidar, R.Ph., Ph.D.
   Chief, Bioequivalence Branch
   Division of Bioequivalence and GLP Compliance (DBGLPC)
   Office of Scientific Investigations (OSI)

SUBJECT: FY 2012, High Priority User Fee NDA, Pre-Approval Data Validation Inspection Bioresearch Monitoring, Human Drugs, CP 7348.001

RE: NDA 21246/S-45 and NDA 21-087/S-62
DRUG: Tamiflu (Oseltamivir Phosphate)
SPONSOR: Hoffmann-La Roche, Inc.

Please note this is an Amendment to the inspection assignment. The analytical site for Study WP20749 has closed, and records have been moved to the [redacted].
This memo requests that you arrange inspections of the clinical and analytical portions of the following pharmacokinetic and safety studies. A DBGLPC scientist with specialized knowledge may participate in the inspections of the analytical sites to provide scientific and technical expertise. Please contact the DBGLPC point of contact (POC) upon receipt of this assignment to arrange scheduling of the analytical inspection. All of these inspections should be completed before [redacted].

Following identification of the FDA investigators, background material will be forwarded directly. Please contact the POC for background materials.

Please do not identify the application type or number, the studies to be inspected, the drug name, or the names of the study investigators prior to the start of inspection.

**Study Number:** WP22849  
**Study Title:** “An open-label, prospective, pharmacokinetic/pharmacodynamic and safety evaluation of Oseltamivir (Tamiflu®) in the treatment of infants 0 to <12 months of age with confirmed influenza infection”

**Clinical Site# 1:** Charité Universitätsmedizin Berlin  
Klinik für Pädiatrie mit Schwerpunkt Pneumologie und Immunologie  
Augustenburger Platz 1  
D-13353 Berlin, Germany  
TEL: +49 30 450-50  
FAX: Not available  
Investigator: Barbara Rath, M.D.  
TEL: +49 30 450-566-182  
Email: Barbara.Rath@gmail.com

**Study Number:** WP20749 (CAG 114)  
**Study Title:** “A pharmacokinetic/pharmacodynamic and safety evaluation of Oseltamivir (Tamiflu®) for the treatment of children less than 24 months of age with confirmed influenza infection (CAG 114)”

**Clinical Site# 1:** University of Texas Southwestern Medical Center at Dallas  
5323 Harry Hines Blvd.  
Dallas, TX 75390  
TEL: (214) 648-3753  
FAX: (214) 648-2481
Clinical Site# 2: Children’s Medical Center  
1935 Medical District Drive  
Dallas, TX 75235  
TEL: (214) 456-7000  

Clinical Site# 3: Parkland Health and Hospitals Systems  
5201 Harry Hines Blvd.  
Dallas, TX 75235  
TEL: (214) 590-8000  

Investigator: Pablo J. Sanchez, M.D.  
(same for sites 1, 2, and 3 in TX)  

Contact Info:  
TEL: (214) 648-3753  
FAX: (214) 648-2481  
Email: pablo.sanchez@utsouthwestern.edu  

Clinical Site# 4: The Children’s Hospital of Alabama  
1600 7th Avenue South  
Birmingham, AL 35233  
TEL: (205) 996-6097, (205) 638-9100  
FAX: (205) 975-9972  

Clinical Site# 5: The University of Alabama Hospital,  
619 19th Street  
Birmingham, AL 35249  
TEL: (205) 934-4011  

Investigator: David Winston Kimberlin, M.D.  
(same for sites 4 and 5 in AL)  

Contact Info:  
TEL: (205) 996-6097; (205) 934-2424  
FAX: (205) 975-9972  
Email: dkimberlin@peds.uab.edu  

Please assure the following during the inspection:  
- Please have the records of all study subjects audited. The subject records in the NDA submission should be compared to the original documents at the site.  
- Please verify the protocol and actual study conduct, IRB approval, inclusion/exclusion criteria, adverse events, concomitant medication, drug accountability, as well as the source documents and case report forms for dosing.  
- Please scrutinize the SOPs for study related procedures.  
- Please check the dosing logs to confirm that correct drug products were administered to the subjects.  
- Please verify that the subjects were compliant with the trial regimen and confirm the presence of 100% of the signed and
dated consent forms, and comment on this informed consent check in the EIR.

- In addition to the standard investigation involving source documents, the correspondence files should be examined for sponsor-requested changes, if any, to the study data or report.

- Please collect relevant exhibits for all findings, including discussion items at closeout, as evidence of the findings.

**ANALYTICAL:**

<table>
<thead>
<tr>
<th>Study Number:</th>
<th>WP22849</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analytical Site:</td>
<td>(b) (4)</td>
</tr>
<tr>
<td>Investigator:</td>
<td>(b) (4)</td>
</tr>
<tr>
<td>Contact Person:</td>
<td>(b) (4)</td>
</tr>
<tr>
<td>Methodology:</td>
<td>LC-MS/MS</td>
</tr>
<tr>
<td>Method code:</td>
<td>PBRL-RD-1018</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study Number:</th>
<th>WP20749 (CASG 114)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Analytical Site:</td>
<td>(b) (4)</td>
</tr>
<tr>
<td>Investigator:</td>
<td>(b) (4)</td>
</tr>
<tr>
<td>Methodology:</td>
<td>LC-MS/MS</td>
</tr>
<tr>
<td>Method code:</td>
<td>SAP.055</td>
</tr>
</tbody>
</table>

**Please confirm the following during the inspection:**

- All pertinent items related to the analytical method used for the measurement of Oseltamivir and Oseltamivir carboxylate concentrations in human plasma should be examined.

- The accuracy of the analytical data provided in the NDA submission by the applicant should be compared with the original documents at the site.
• The method validation and the actual assay of the subject plasma samples, the variability between and within runs, QC, demonstration of accuracy and precision in matrix using standards and QCs prepared from separate stocks, stability of subject samples covered by validated stability period.

• Scrutinize the number of repeat assays of the subject plasma samples, and the reason for such repetitions, the SOP(s) for repeat assays and other study specific procedures.

• In addition to the standard investigation involving the source documents, the files of communication between the analytical site and the sponsor should be examined for their content.

In addition to the compliance program elements, additional study specific instructions, if any, may be provided by the DBGLPC POC prior to commencement of the inspection. Therefore, we request that the DBGLPC/OSI reviewer or POC be contacted for any further follow-up instructions before the inspection regarding any data anomalies or questions noted during review of study report. The ORA investigator should contact the DBGLPC POC for inspection related questions or clarifications.

Please fax/email a copy of Form FDA 483 if issued, as soon as possible. If at close-out of the inspection, it appears that the violations may warrant an OAI classification, please notify the POC as soon as possible. At completion of inspection, please remind the inspected entity of the 15 business-day timeframe for submission of a written response to observations listed on Form FDA 483. Please forward written response as soon as you receive to Sam Haidar and POC (Fax: 1-301-847-8748 or Email: sam.haidar@fda.hhs.gov).

DBGLPC Point of Contact: Foreign Sites
Arindam Dasgupta, Ph.D.
(301) 796-3326
arindam.dasgupta@fda.hhs.gov

Domestic Sites
Jyoti B. Patel, Ph.D.
(301) 796-4617
jyoti.patel@fda.hhs.gov

CC:
CDER OSI PM TRACK
OSI/DBGC/Taylor/Haidar/Skelly/Patel/Dasgupta/Biswa/Dejernett/CF
HFC-130/ORA HQ DFFI IOB BIMO
OND/OAP/DAVP/Thompson
OTS/OCP/DCP4/Zheng
HFR-SW150/Turcovski (DIB)/
HFR-SW1540/Martinez (BIMO)/HFR-SW1515/Alanna Bias (BIMO)
HFR-SE350/Clarida (DIB)/HFR-SE450/Abel/Blakely (BIMO)
HFR-CE750/Jasukaitis (DIB)/Bellamy (BIMO)
Draft: JBP 8/21/2012
Edit: GB 8/22/2012, MFS/8/22/2012
Amend: JBP 8/24/2012, MFS 8/24/2012
OSI File #6368; O:\BE\assigns\amendbio21246.doc
FACTS: 1434272
ECMS: Cabinets/CDER_OC/OSI/Division of Bioequivalence & Good Laboratory Practice Compliance/Electronic Archive/BEB
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JYOTI B PATEL
08/24/2012

MICHAEL F SKELLY
08/24/2012
Skelly signing on behalf of Dr. Haidar
DATE: August 22, 2012

TO: Associate Director
   International Operations Drug Group
   Division of Foreign Field Investigations

From: Sam H. Haidar, R.Ph., Ph.D.
   Chief, Bioequivalence Branch
   Division of Bioequivalence and GLP Compliance (DBGLPC)
   Office of Scientific Investigations (OSI)

SUBJECT: FY 2012, High Priority User Fee NDA, Pre-Approval Data Validation Inspection Bioresearch Monitoring, Human Drugs, CP 7348.001

RE: NDA 21246/S-45 and NDA 21-087/S-62
DRUG: Tamiflu (Oseltamivir Phosphate)
SPONSOR: Hoffmann-La Roche, Inc.

This memo requests that you arrange inspections of the clinical and analytical portions of the following pharmacokinetic and safety studies. A DBGLPC scientist with specialized knowledge may participate in the inspections of the analytical sites to provide scientific and technical expertise. Please contact the DBGLPC point of contact (POC) upon receipt of this assignment to arrange scheduling of the analytical inspection. All of these inspections should be completed before...

Following identification of the FDA investigators, background...
material will be forwarded directly. Please contact the POC for background materials

Please do not identify the application type or number, the studies to be inspected, the drug name, or the names of the study investigators prior to the start of inspection.

**Study Number:** WP22849  
**Study Title:** “An open-label, prospective, pharmacokinetic/pharmacodynamic and safety evaluation of Oseltamivir (Tamiflu®) in the treatment of infants 0 to < 12 months of age with confirmed influenza infection”

**Clinical Site #1:** Charité Universitätsmedizin Berlin  
Klinik für Pädiatrie mit Schwerpunkt Pneumologie und Immunologie  
Augustenburger Platz 1  
D-13353 Berlin, Germany  
TEL: +49 30 450-50  
FAX: Not available

**Investigator:** Barbara Rath, M.D.  
TEL: +49 30 450-566-182  
Email: Barbara.Rath@gmail.com

**Study Number:** WP20749  
**Study Title:** “A pharmacokinetic/pharmacodynamic and safety evaluation of Oseltamivir (Tamiflu®) for the treatment of children less than 24 months of age with confirmed influenza infection (CASG 114)”

**Clinical Site #1:** University of Texas Southwestern Medical Center at Dallas  
5323 Harry Hines Blvd.  
Dallas, TX 75390  
TEL: (214)648-3753  
FAX: (214)648-2481

**Clinical Site #2:** Children’s Medical Center  
1935 Medical District Drive  
Dallas, TX 75235  
TEL: (214)456-7000

**Clinical Site #3:** Parkland Health and Hospitals Systems  
5201 Harry Hines Blvd.  
Dallas, TX 75235  
TEL: (214)590-8000

Reference ID: 3178505
Please assure the following during the inspection:

- Please have the records of all study subjects audited. The subject records in the NDA submission should be compared to the original documents at the site.
- Please verify the protocol and actual study conduct, IRB approval, inclusion/exclusion criteria, adverse events, concomitant medication, drug accountability, as well as the source documents and case report forms for dosing.
- Please scrutinize the SOPs for study related procedures.
- Please check the dosing logs to confirm that correct drug products were administered to the subjects.
- Please verify that the subjects were compliant with the trial regimen and confirm the presence of 100% of the signed and dated consent forms, and comment on this informed consent check in the EIR.
- In addition to the standard investigation involving source documents, the correspondence files should be examined for sponsor-requested changes, if any, to the study data or report.
- Please collect relevant exhibits for all findings, including discussion items at closeout, as evidence of the findings.
**ANALYTICAL:**

<table>
<thead>
<tr>
<th>Study Number:</th>
<th>WP22849</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Analytical Site:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Investigator:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Person:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Methodology:</strong></td>
<td>LC-MS/MS</td>
</tr>
<tr>
<td><strong>Method code:</strong></td>
<td>PBRL-RD-1018</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study Number:</th>
<th>WP20749</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Analytical Site:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Investigator:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Contact Person:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Methodology:</strong></td>
<td>LC-MS/MS</td>
</tr>
<tr>
<td><strong>Method code:</strong></td>
<td>SAP.055</td>
</tr>
</tbody>
</table>

Please confirm the following during the inspection:

- All pertinent items related to the analytical method used for the measurement of Oseltamivir and Oseltamivir carboxylate concentrations in human plasma should be examined.

- The accuracy of the analytical data provided in the NDA submission by the applicant should be compared with the original documents at the site.

- The method validation and the actual assay of the subject plasma samples, the variability between and within runs, QC, demonstration of accuracy and precision in matrix using standards and QCs prepared from separate stocks, stability of subject samples covered by validated stability period.
• Scrutinize the number of repeat assays of the subject plasma samples, and the reason for such repetitions, the SOP(s) for repeat assays and other study specific procedures.
• In addition to the standard investigation involving the source documents, the files of communication between the analytical site and the sponsor should be examined for their content.

In addition to the compliance program elements, additional study specific instructions, if any, may be provided by the DBGLPC POC prior to commencement of the inspection. Therefore, we request that the DBGLPC/OSI reviewer or POC be contacted for any further follow-up instructions before the inspection regarding any data anomalies or questions noted during review of study report. The ORA investigator should contact the DBGLPC POC for inspection related questions or clarifications.

Please fax/email a copy of Form FDA 483 if issued, as soon as possible. If at close-out of the inspection, it appears that the violations may warrant an OAI classification, please notify the POC as soon as possible. At completion of inspection, please remind the inspected entity of the 15 business-day timeframe for submission of a written response to observations listed on Form FDA 483. Please forward written response as soon as you receive to Sam Haidar and POC (Fax: 1-301-847-8748 or Email: sam.haidar@fda.hhs.gov).

DBGLPC Point of Contact: Foreign Sites
Arindam Dasgupta, Ph.D.
(301) 796-3326
arindam.dasgupta@fda.hhs.gov

Domestic Sites
Jyoti B. Patel, Ph.D.
(301) 796-4617
jyoti.patel@fda.hhs.gov

CC:
CDER OSI PM TRACK
OSI/DBG/CG/Emory/Haidar/Skelly/Patel/Dasgupta/Biswas/Dejernett/CF
HFC-130/ORA/OSI DFFI IOB BIMO
OND/OAP/DAVP/Thompson
OTS/OC/DCP4/Zheng
HFR-SW150/Turcovski (DIB)/
HFR-SW1540/Martinez (BIMO)/HFR-SW1515/Alanna Bias (BIMO)
HFR-SE350/Clarida (DIB)/HFR-SE450/Abel/Blakely (BIMO)
Draft: JBP 8/21/2012
Edit: GB 8/22/2012, MFS/8/22/2012
Tamiflu (Oseltamivir Phosphate)

OSI File #6368; O:\BE\assigns\bio21246.doc

FACTS: 1434272

ECMS: Cabinets/CDER_OC/OSI/Division of Bioequivalence & Good Laboratory Practice Compliance/Electronic Archive/BEB
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JYOTI B PATEL
08/22/2012

MICHAEL F SKELLY
08/23/2012
Skelly signing on behalf of Dr. Haidar

WILLIAM H TAYLOR
08/23/2012